Palavras-chave
Crianças
Adolescentes
Sistema de infusão de insulina
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Investigar o impacto do uso de sistemas de infusão contínua de insulina no controle glicêmico de pacientes pediátricos com DM1. Métodos: Realizou-se uma revisão sistemática com registro no PROSPERO (CRD420261358186) a fim de garantir transparência metodológica. A estratégia de busca foi construída com descritores DeCS/MeSH. As buscas foram realizadas nas bases PubMed, Portal CAPES e Cochrane. Foram incluídos estudos dos últimos 5 anos, pacientes com diagnóstico de DM1 até 18 anos. 19 estudos foram incluídos nesta revisão. Resultados: Estudos com crianças de 1 a 7 anos demonstraram aumento significativo do TIR e redução da HbA1c, sem aumento de hipoglicemia. Em crianças de 6 a 12 anos observou-se redução do tempo em hipoglicemia e melhora do controle metabólico. Crianças muito pequenas apresentaram incremento absoluto de aproximadamente 8–9 pontos percentuais no TIR. Sistemas híbridos avançados mantiveram benefícios ao longo do período de intervenção, com redução de hipoglicemia e menor exposição à hiperglicemia. Estudos também relataram melhora na satisfação com o tratamento, redução do medo de hipoglicemia e menor carga no manejo do diabetes. Considerações finais: Sistemas automatizados de infusão contínua de insulina apresentam benefícios clínicos relevantes no controle glicêmico de crianças e adolescentes com DM1, promovendo melhora metabólica e psicossocial.
Referências
AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE FOR DIABETES. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S150-S165.
BOMBACI B, et al. Impact of automated insulin delivery systems in children and adolescents with type 1 diabetes previously treated with multiple daily injections: A single-center real-world study. Medicina, 2025; 61(9): 1602.
BOMBACI B, et al. One-year real-world study on comparison among different continuous subcutaneous insulin infusion devices for the management of pediatric patients with type 1 diabetes: The supremacy of hybrid closed-loop systems. International Journal of Environmental Research and Public Health, 2022; 19(16): 10293.
BOMBACI B, et al. Real-world performance of first- versus second-generation automated insulin delivery systems on a pediatric population with type 1 diabetes: A one-year observational study. Journal of Diabetes Science and Technology, 2025; 19(1): 98–104.
DESALVO DJ, et al. Glycemic outcomes persist for up to 2 years in very young children with the Omnipod® 5 automated insulin delivery system. Diabetes Technology & Therapeutics, 2024; 26(6): 383–393.
DICKINSON I, et al. Technology usage and glycaemic outcomes in a single tertiary centre with an ethnically diverse and socioeconomically deprived cohort of children with type 1 diabetes mellitus. Frontiers in Clinical Diabetes and Healthcare, 2025; 5: 1417287.
DOVC K, et al. Consistent efficacy and safety of automated insulin delivery in children aged 2–6 years: Results from the LENNY trial continuation phase. Diabetes Research and Clinical Practice, 2025; 230: 112934.
FORLENZA GP, et al. Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatric Diabetes, 2022; 23(3): 324–329.
HU S, et al. Clinical outcome and cost-effectiveness analysis of CSII versus MDI in children and adolescent with type 1 diabetes mellitus in a public health care system of China. Frontiers in Endocrinology, 2021; 12: 604028.
KANAPKA LG, et al. Extended use of the Control-IQ closed-loop control system in children with type 1 diabetes. Diabetes Care, 2021; 44(2): 473–478.
KARIYAWASAM D, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: A randomised, controlled, cross-over, non-inferiority trial. The Lancet Digital Health, 2022; 4(3): e158–e168.
MESSER LH, et al. Positive impact of the bionic pancreas on diabetes control in youth 6–17 years old with type 1 diabetes: A multicenter randomized trial. Diabetes Technology & Therapeutics, 2022; 24(10): 712–725.
PETROVSKI G, et al. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: Drivers to successful outcomes. Acta Diabetologica, 2021; 58(2): 207–213.
PIHOKER C, et al. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. Diabetes Technology & Therapeutics, 2023; 25(11): 755–764.
RAPINI N, et al. Efficacy and safety of advanced hybrid closed-loop systems in children with type 1 diabetes younger than 6 years. Frontiers in Endocrinology, 2024; 15: 1382920.
SHERR JL, et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: A single-arm multicenter clinical trial. Diabetes Care, 2022; 45(8): 1907–1910.
WADWA RP, et al. Trial of hybrid closed-loop control in young children with type 1 diabetes. New England Journal of Medicine, 2023; 388(11): 991–1001.
WARE J, et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. New England Journal of Medicine, 2022; 386(3): 209–219.
WARE J, et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: A multicentre 6-month randomised controlled trial. The Lancet Digital Health, 2022; 4(4): e245–e255.
WARE J, et al. Effect of 48 months of closed-loop insulin delivery on residual C-peptide secretion and glycemic control in newly diagnosed youth with type 1 diabetes: A randomized trial. Diabetes Care, 2024; 47(8): 1441–1448.
WARE J, et al. Eighteen-month hybrid closed-loop use in very young children with type 1 diabetes: A single-arm multicenter trial. Diabetes Care, 2024; 47(12): 2189–2195.